EXETER, NH, March 13, 2015 – Vapotherm, Inc., a developer and manufacturer of advanced respiratory care technology, today announced the closing of a $20MM equity financing. 3×5 Specialty Opportunity Fund led the financing round, which also included current investors QuestMark Partners, Gilde Healthcare Partners, Morgenthaler Ventures, Kaiser Permanente, Adage Capital Management, Crestline Investors and Cross Creek Capital.
Tony Arnerich General Partner of 3×5 Special Opportunity Fund commented “We are excited about Vapotherm’s unique High Flow Therapy solution which improves clinical outcomes for patients with chronic and acute breathing disorders.”
“This new capital will be used to continue to build out our direct sales organization in the U.S. and to develop our next generation solutions. We appreciate the continued support of our investors as we build a leading respiratory care company,” said Joe Army, President and CEO of Vapotherm.
Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 1,000,000 patients have been treated with Vapotherm High Flow Therapy. For more information, visit www.vapotherm.com.
Contact: John Landry, VP & CFO (603) 658-0011